Format
Items per page
Sort by

Send to:

Choose Destination

Results: 15

Related Articles by Review for PubMed (Select 9661897)

1.

Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J.

Cancer Res. 1998 Jul 1;58(13):2825-31. Erratum in: Cancer Res 1999 Apr 15;59(8):2020.

2.

Interaction between Herceptin and taxanes.

DiƩras V, Beuzeboc P, Laurence V, Pierga JY, Pouillart P.

Oncology. 2001;61 Suppl 2:43-9. Review.

PMID:
11694787
3.

Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.

Hirsch FR, Helfrich B, Franklin WA, Varella-Garcia M, Chan DC, Bunn PA Jr.

Clin Breast Cancer. 2002 May;3 Suppl 1:12-6. Review.

PMID:
12057039
4.

[Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].

Dank M.

Orv Hetil. 2001 Nov 18;142(46):2563-8. Review. Hungarian.

PMID:
11770175
7.

Targeting HER2: recent developments and future directions for breast cancer patients.

Wang SC, Zhang L, Hortobagyi GN, Hung MC.

Semin Oncol. 2001 Dec;28(6 Suppl 18):21-9. Review.

PMID:
11774202
8.

From HER2 to herceptin.

Mokbel K, Hassanally D.

Curr Med Res Opin. 2001;17(1):51-9. Review.

PMID:
11464447
9.
10.

[Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene?].

Beuzeboc P, Scholl S, Garau XS, Vincent-Salomon A, Cremoux PD, Couturier J, PalangiƩ T, Pouillart P.

Bull Cancer. 1999 Jun;86(6):544-9. Review. French.

PMID:
10417428
11.

Can trastuzumab be effective against tumors with low HER2/Neu (ErbB2) receptors?

Arteaga CL.

J Clin Oncol. 2006 Aug 10;24(23):3722-5. Epub 2006 Jul 17. Review. No abstract available.

PMID:
16847283
12.

Perceptions of Herceptin: a monoclonal antibody for the treatment of breast cancer.

Dillman RO.

Cancer Biother Radiopharm. 1999 Feb;14(1):5-10. Review.

PMID:
10850281
13.

HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.

Baselga J, Seidman AD, Rosen PP, Norton L.

Oncology (Williston Park). 1997 Mar;11(3 Suppl 2):43-8. Review.

14.

The future of targeted therapy: combining novel agents.

Gianni L.

Oncology. 2002;63 Suppl 1:47-56. Review.

PMID:
12422055
15.

[Chemosensitivity test of breast cancer].

Oura S, Tanino H, Naito Y.

Nihon Rinsho. 2000 Apr;58 Suppl:581-6. Review. Japanese. No abstract available.

PMID:
11026054
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk